Theodore A. Gooley
Ph.D., University of Arizona, Applied Mathematics, 1990.
B.S., Washington State University, Mathematics, 1984.
Clinical trials and methods of data analysis in stem cell transplantation.
The Clinical Research Division at the FHCRC performs more stem cell transplants than any other institution in the world. The first transplant in Seattle was done in 1969, and currently roughly 450 transplants are done yearly. These facts put the FHCRC in a unique position to conduct both small- and large-scale clinical trials designed to address some of the most important and interesting questions that face the transplantation community today. The large volume of data generated from past transplants also provides a rich database from which information can be used to generate hypotheses and to monitor progress made in the field.
In recent years, many dose-finding studies have been designed within the Clinical Division with the goal of determining whether of not an effective dose of a treatment can be found such that the dose appears both safe and efficacious. This is in contrast to the more standard Phase I setting where one may be concerned only with safety and not efficacy. One such example is selective depletion of T cells in the donor marrow, where it is desired to find a dose of T cells that is associated with acceptable rates of graft failure while at the same timebeing associated with acceptable rates of severe graft-versus-host disease.
With the advent of the National Marrow Donor Program, use of alternative donors is becoming more commonplace for patients who lack a suitable family-member donor. It has beenshown in certain diseases that the time from diagnosis to transplant is an important prognostic factor in predicting outcome after transplantation and that outcome is adversely affected by donors who fail to share certain HLA antigens with the patient. A decision often needs to be made by both patient and physician whether to get transplanted early with a less-than-optimal donor or to wait longer in the hope of finding a more suitable donor. We are currently in the process of dealing with these and related issues for patients with chronic myeloid leukemia who receive a transplant from an unrelated donor.
The prevention and treatment of fungal and viral infections continues to be a problem following stem cell transplantation due to the immunocompromised condition of the patient. We have completed several randomized, controlled trials in recent years, and others are currently underway. These trials have led to significant progress in the prevention and treatment of certain infections, and the resultsof past and current clinical trials continue to shape strategies used to deal with such complications.
American Statistical Association
Society for American Baseball Research
Society for Clinical Trials
Honors and Awards
Phi Beta Kappa
Phi Kappa Phi
2002-2006, Affiliate Associate Professor, University of Washington, School of Public Health and Community Medicine, Biostatistics
1999-2005, Associate Member, Fred Hutchinson Cancer Research Center, Clinical Research Division, Clinical Statistics
1999-2005, Associate Member (Joint Appointment), Fred Hutchinson Cancer Research Center, Public Health Sciences Division, Biostatistics
1993-2002, Affiliate Assistant Professor, University of Washington, School of Public Health and Community Medicine, Biostatistics
1992-1999, Assistant Member, Fred Hutchinson Cancer Research Center, Clinical Statistics, Clinical Research Division
1992-1999, Assistant Member (Joint Appointment), Fred Hutchinson Cancer Research Center, Public Health Sciences Division
1991-1992, Post-Doctoral Fellow, University of Rochester, Statistics
1984-1986, Graduate Teaching Assistant, University of Arizona, Mathematics
1983-1984, Undergraduate Teaching Assistant, Washington State University, College of Sciences, Mathematics
MHC-Resident Variation Affects Risks After Unrelated Donor Hematopoietic Cell Transplantation.. Science translational medicine. 4(144):144ra101.. 2012.
Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results.. Bone marrow transplantation. 47(7):946-951.. 2012.
A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(9):1308-15.. 2011.
Extracorporeal photopheresis in addition to pentostatin in conditioning for canine hematopoietic cell transplantation: role in engraftment.. Bone marrow transplantation. 46(10):1382-8.. 2011.
Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(10):1537-45.. 2011.
Who will manage American patients with diabetes? Residents' career preferences and perceptions of diabetes care. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 17(2):235-9.. 2011.
Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells.. Proceedings of the National Academy of Sciences of the United States of America. 108(10):4081-6.. 2011.
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(9):1190-7.. 2011.
Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(6):908-15.. 2011.
Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(8):1187-95.. 2011.
Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.. British journal of haematology. 153(1):76-82.. 2011.
Blood and gastric FOXP3+ T cells are not decreased in human gastric graft-versus-host disease.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(4):486-96.. 2011.
The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes.. Blood. 116(13):2304-14.. 2010.
HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(10):1382-7.. 2010.
Reduced mortality after allogeneic hematopoietic-cell transplantation.. The New England journal of medicine. 363(22):2091-101.. 2010.
Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.. British journal of haematology. 150(2):170-8.. 2010.
Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 24(7):1276-82.. 2010.